Plain-English translation of NCT05657652 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether a combination of three medications — venetoclax, cladribine, and low-dose cytarabine — can help people whose acute lymphoblastic leukemia (a blood cancer) has returned after treatment or didn't respond to initial therapy. Right now, doctors don't have many good options for these patients, and existing treatments are either very expensive or don't work well. This trial will see if this new medication combination is both effective and safe.
When acute lymphoblastic leukemia comes back or doesn't respond to standard treatment, patients have very limited options. Current approaches are either too costly for most people or have low success rates. This trial exists to find out whether this medication combination could offer a better, more affordable path forward for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You would receive the three-medication combination as part of your treatment plan, likely through visits at the hospital or clinic where your doctor oversees your care. The study will monitor how well the treatment works and how your body responds to it. You'll be one of about 36 patients enrolled in this trial across multiple centers, and your doctors will carefully watch for both benefits and any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Sponsor
The First Affiliated Hospital of Soochow University
Collaborators
Jining Medical University, The Second People's Hospital of Huai'an
Enrollment target
~36 participants
Started
October 2022
Primary completion
October 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
15 Years – 70 Years
Last updated on clinicaltrials.gov in December 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.